Travere Therapeutics (TVTX) closed at $50.85 on October 28, 2026, down 0.1% from the previous close, on volume of 1,257,325 shares (30-day average 1,984,303).
Data as of October 28, 2026.
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Business Wire (Mon, 26-Oct 4:30 PM ET)
TipRanks (Mon, 26-Oct 7:30 AM ET)
Business Wire (Fri, 23-Oct 7:20 PM ET)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 12-Oct 5:00 PM ET)
Business Wire (Fri, 2-Oct 10:00 AM ET)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 9:58 AM ET)
Business Wire (Wed, 23-Sep 7:00 AM ET)
Market Chameleon (Tue, 22-Sep 5:46 AM ET)
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Business Wire (Mon, 21-Sep 4:05 PM ET)
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Business Wire (Thu, 17-Sep 4:30 PM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of October 28, 2026, TVTX stock price declined to $50.85 with 1,257,325 million shares trading.
TVTX has a beta of 1.84, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.13 to the broad based SPY ETF.
TVTX has a market cap of $4.73 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $170 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $10 million and missed earnings estimates by -$.33.
In the last 3 years, TVTX traded as high as $68.73 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.
TVTX has outperformed the market in the last year with a return of +70.8%, while the SPY ETF gained +13.8%. However, in the most recent history, TVTX shares have underperformed the stock market with its stock returning -10.3% in the last 3 month period and -1.8% for the last 2 week period, while SPY has returned +4.8% and -0.7%, respectively.
TVTX support price is $49.40 and resistance is $52.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.
